Former Aetna CEO cites ‘tension’ in CVS board changes

The former CEO of health insurer Aetna, which was acquired by CVS Health for $69 billion at the end of 2018, says he is being pushed off the board of the combined company.

CVS Health recently announced it would drop three board members after its 2020 Annual Meeting, including Former Aetna CEO Mark Bertolini and two other directors. While CVS stated the change from 16 board members to 13 is more aligned with corporate governance best practices, Bertolini told The Wall Street Journal he was willing to serve on the board to support the integration between Aetna and CVS. According to CVS’ statement, the companies are integrated. But to Bertolini, the “integration is far from over,” he told the WSJ.

He also said there is “a natural tension” between the former CEO and the CEO of CVS Health, Larry Merlo, as there would be with any transaction.

The conflicting statements between CVS Health and Bertolini hint that at other potential management questions.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.